Selected research
Industry Growth & Trends
Global Cancer Biopharmaceuticals Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Cancer Biopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Cancer Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Cancer Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cancer Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Cancer Biopharmaceuticals market include Sanofi, Johnson & Johnson, Novartis, Merck, Mylan, Eli Lilly, Pfizer, GlaxoSmithKline and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Cancer Biopharmaceuticals market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Cancer Biopharmaceuticals market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cancer Biopharmaceuticals market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cancer Biopharmaceuticals.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Cancer Biopharmaceuticals market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Cancer Biopharmaceuticals Market by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Mylan
Eli Lilly
Pfizer
GlaxoSmithKline
AstraZeneca
LEO Pharma
Elusys Therapeutics
Bristol-Myers Squibb
Boehringer Ingelheim
Alexion Pharmaceuticals
Agios Pharmaceuticals
Cancer Biopharmaceuticals Segment by Type
Biologics
Biosimilars
Cancer Biopharmaceuticals Segment by Application
Liquid Cancers
Solid Cancers
Cancer Biopharmaceuticals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Biopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Cancer Biopharmaceuticals companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Biologics
- Biosimilars
Applications
- Liquid Cancers
- Solid Cancers
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck
- Mylan
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- LEO Pharma
- Elusys Therapeutics
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Alexion Pharmaceuticals
- Agios Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Cancer Biopharmaceuticals Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Cancer Biopharmaceuticals Market Size by Region (2021-2032)
- 1.4.1 Global Cancer Biopharmaceuticals Market Size by Region (2021-2026)
- 1.4.2 Global Cancer Biopharmaceuticals Market Size by Region (2027-2032)
- 1.5 Key Regions Cancer Biopharmaceuticals Market Size (2021-2032)
- 1.5.1 North America Cancer Biopharmaceuticals Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Cancer Biopharmaceuticals Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Cancer Biopharmaceuticals Market Size Growth Rate (2021-2032)
- 1.5.4 South America Cancer Biopharmaceuticals Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Cancer Biopharmaceuticals Market Size Growth Rate (2021-2032)
2 Cancer Biopharmaceuticals Market by Type
- 2.1 Type Introduction
- 2.1.1 Biologics
- 2.1.2 Biosimilars
- 2.2 Global Cancer Biopharmaceuticals Market Size by Type
- 2.2.1 Global Cancer Biopharmaceuticals Market Size Overview by Type (2021-2032)
- 2.2.2 Global Cancer Biopharmaceuticals Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Cancer Biopharmaceuticals Market Size Forecasted by Type (2027-2032)
- 2.3 Global Cancer Biopharmaceuticals Market Size by Regions
- 2.3.1 North America Cancer Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Cancer Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Cancer Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Cancer Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Cancer Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
3 Cancer Biopharmaceuticals Market by Application
- 3.1 Type Introduction
- 3.1.1 Liquid Cancers
- 3.1.2 Solid Cancers
- 3.2 Global Cancer Biopharmaceuticals Market Size by Application
- 3.2.1 Global Cancer Biopharmaceuticals Market Size Overview by Application (2021-2032)
- 3.2.2 Global Cancer Biopharmaceuticals Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Cancer Biopharmaceuticals Market Size Forecasted by Application (2027-2032)
- 3.3 Global Cancer Biopharmaceuticals Market Size by Regions
- 3.3.1 North America Cancer Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Cancer Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Cancer Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Cancer Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Cancer Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Cancer Biopharmaceuticals Industry Trends
- 4.2 Cancer Biopharmaceuticals Industry Drivers
- 4.3 Cancer Biopharmaceuticals Industry Opportunities and Challenges
- 4.4 Cancer Biopharmaceuticals Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Cancer Biopharmaceuticals Revenue (2021-2026)
- 5.2 Global Cancer Biopharmaceuticals Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Cancer Biopharmaceuticals Key Company Headquarters & Area Served
- 5.4 Global Cancer Biopharmaceuticals Company, Product Type & Application
- 5.5 Global Cancer Biopharmaceuticals Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Cancer Biopharmaceuticals Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Cancer Biopharmaceuticals Players Market Share by Revenue in 2025
- 5.6.3 2025 Cancer Biopharmaceuticals Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Sanofi
- 6.1.1 Sanofi Company Information
- 6.1.2 Sanofi Business Overview
- 6.1.3 Sanofi Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Sanofi Cancer Biopharmaceuticals Product Portfolio
- 6.1.5 Sanofi Recent Developments
- 6.2 Johnson & Johnson
- 6.2.1 Johnson & Johnson Company Information
- 6.2.2 Johnson & Johnson Business Overview
- 6.2.3 Johnson & Johnson Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Johnson & Johnson Cancer Biopharmaceuticals Product Portfolio
- 6.2.5 Johnson & Johnson Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Novartis Cancer Biopharmaceuticals Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Merck
- 6.4.1 Merck Company Information
- 6.4.2 Merck Business Overview
- 6.4.3 Merck Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Merck Cancer Biopharmaceuticals Product Portfolio
- 6.4.5 Merck Recent Developments
- 6.5 Mylan
- 6.5.1 Mylan Company Information
- 6.5.2 Mylan Business Overview
- 6.5.3 Mylan Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Mylan Cancer Biopharmaceuticals Product Portfolio
- 6.5.5 Mylan Recent Developments
- 6.6 Eli Lilly
- 6.6.1 Eli Lilly Company Information
- 6.6.2 Eli Lilly Business Overview
- 6.6.3 Eli Lilly Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Eli Lilly Cancer Biopharmaceuticals Product Portfolio
- 6.6.5 Eli Lilly Recent Developments
- 6.7 Pfizer
- 6.7.1 Pfizer Company Information
- 6.7.2 Pfizer Business Overview
- 6.7.3 Pfizer Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Pfizer Cancer Biopharmaceuticals Product Portfolio
- 6.7.5 Pfizer Recent Developments
- 6.8 GlaxoSmithKline
- 6.8.1 GlaxoSmithKline Company Information
- 6.8.2 GlaxoSmithKline Business Overview
- 6.8.3 GlaxoSmithKline Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 GlaxoSmithKline Cancer Biopharmaceuticals Product Portfolio
- 6.8.5 GlaxoSmithKline Recent Developments
- 6.9 AstraZeneca
- 6.9.1 AstraZeneca Company Information
- 6.9.2 AstraZeneca Business Overview
- 6.9.3 AstraZeneca Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 AstraZeneca Cancer Biopharmaceuticals Product Portfolio
- 6.9.5 AstraZeneca Recent Developments
- 6.10 LEO Pharma
- 6.10.1 LEO Pharma Company Information
- 6.10.2 LEO Pharma Business Overview
- 6.10.3 LEO Pharma Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 LEO Pharma Cancer Biopharmaceuticals Product Portfolio
- 6.10.5 LEO Pharma Recent Developments
- 6.11 Elusys Therapeutics
- 6.11.1 Elusys Therapeutics Company Information
- 6.11.2 Elusys Therapeutics Business Overview
- 6.11.3 Elusys Therapeutics Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Elusys Therapeutics Cancer Biopharmaceuticals Product Portfolio
- 6.11.5 Elusys Therapeutics Recent Developments
- 6.12 Bristol-Myers Squibb
- 6.12.1 Bristol-Myers Squibb Company Information
- 6.12.2 Bristol-Myers Squibb Business Overview
- 6.12.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Bristol-Myers Squibb Cancer Biopharmaceuticals Product Portfolio
- 6.12.5 Bristol-Myers Squibb Recent Developments
- 6.13 Boehringer Ingelheim
- 6.13.1 Boehringer Ingelheim Company Information
- 6.13.2 Boehringer Ingelheim Business Overview
- 6.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Boehringer Ingelheim Cancer Biopharmaceuticals Product Portfolio
- 6.13.5 Boehringer Ingelheim Recent Developments
- 6.14 Alexion Pharmaceuticals
- 6.14.1 Alexion Pharmaceuticals Company Information
- 6.14.2 Alexion Pharmaceuticals Business Overview
- 6.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Alexion Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio
- 6.14.5 Alexion Pharmaceuticals Recent Developments
- 6.15 Agios Pharmaceuticals
- 6.15.1 Agios Pharmaceuticals Company Information
- 6.15.2 Agios Pharmaceuticals Business Overview
- 6.15.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Agios Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio
- 6.15.5 Agios Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Cancer Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 7.3 North America Cancer Biopharmaceuticals Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Cancer Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 8.3 Europe Cancer Biopharmaceuticals Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Cancer Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Cancer Biopharmaceuticals Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Cancer Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 10.3 South America Cancer Biopharmaceuticals Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Cancer Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Cancer Biopharmaceuticals Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst